First Hit

Previous Doc

Next Doc

Go to Doc#

**End of Result Set** 

©enerate Collection Print

L11: Entry 5 of 5

File DWPI

Spenish ALL

Feb 26, 2004

DERWENT-ACC-NO: 1995-272839

DERWENT-WEEK: 200416

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: <u>HIV</u> virus activity inhibitor - obtained by inoculating <u>Lentinus edodes hypha</u> onto lagasse solid medium cultivating dissociating, <u>extracting</u> and inactivating

enzyme

INVENTOR: NAGAOKA, H

PATENT-ASSIGNEE: NAGAOKA H (NAGAI)

PRIORITY-DATA: 1993JP-0317564 (December 17, 1993)

පිතෙල්ක පිත්තුන්තර

		TIGIL STATES	SEEMINIALS GEE			
ENT_EAMILV.						
PUB-NO		PUB-DATE	LANGUAGI	PAGES	MAIN-IPC	
US 20040038330 A	<u>A1</u>	February 26, 20	04	000	C12P001/00	
JP 07173070 A		July 11, 1995		006	A61K035/84	
TW 251238 A		July 11, 1995		000		
CN 1106695 A		August 16, 1995		000	A61K035/84	
JP 3017630 B2		March 13, 2000		005	A61K035/84	
KR 149477 B1		October 15, 199	8	000	A61K035/66	
			•			
LICATION-DATA:						
B-NO	APPL-DATE		APPL-NO	DESC	DESCRIPTOR	
0040038330A1	June 9, 1994		1994US-0257355	Cont	Cont of	
0040038330A1	August 25, 1995		1995US-0519293	Div	Div ex	
0040038330A1	August 19, 2003		2003US-0644221	-		
07173070A	December 17, 1993		1993JP-0317564	<u> </u>		
251238A	March 10, 1994		1994TW-0102087	1		
1106695A	March	15, 1994	1994CN-0103012	<b>!</b>		
3017630B2	Decemb	er 17, 1993	1993JP-0317564			
3017630B2			JP 7173070	Prev	rious Publ.	
149477B1	April	4. 1994	1994KR-0007098	3		
	US 20040038330 A  TW 251238 A  CN 1106695 A  JP 3017630 B2  KR 149477 B1  LICATION-DATA: 3-NO 20040038330A1 20040038330A1 20040038330A1 20040038330A1 21040038330A1 2106695A 3017630B2 3017630B2	PUB-NO  US 20040038330 A1  TW 251238 A  CN 1106695 A  JP 3017630 B2  KR 149477 B1  LICATION-DATA: 3-NO APPL-D 20040038330A1 June 9 20040038330A1 August 20040038330A1 August 20040038330A1 August 20040038330A1 August 20040038330A1 Decemb 251238A March 1106695A March 3017630B2 Decemb	PUB-NO PUB-DATE  US 20040038330 A1 February 26, 20  JP 07173070 A  July 11, 1995  TW 251238 A  July 11, 1995  August 16, 1995  JP 3017630 B2 March 13, 2000  KR 149477 B1 October 15, 199  LICATION-DATA: 3-NO APPL-DATE 20040038330A1 August 25, 1995 20040038330A1 August 25, 1995 20040038330A1 August 19, 2003 07173070A December 17, 1993 251238A March 10, 1994 1106695A March 15, 1994 3017630B2 December 17, 1993 3017630B2	PUB-NO PUB-DATE LANGUAGE  US 20040038330 Al February 26, 2004  JP 07173070 A July 11, 1995  TW 251238 A July 11, 1995  CN 1106695 A August 16, 1995  JP 3017630 B2 March 13, 2000  KR 149477 Bl October 15, 1998  LICATION-DATA: 3-NO APPL-DATE APPL-NO 20040038330Al June 9, 1994 1994US-0257355 20040038330Al August 25, 1995 1995US-0519293 20040038330Al August 19, 2003 2003US-0644221 207173070A December 17, 1993 1993JP-0317564 251238A March 10, 1994 1994TW-0102087 3017630B2 December 17, 1993 1993JP-0317564 3017630B2 JP 7173070	PUB-NO         PUB-DATE         LANGUAGE         PAGES           US 20040038330 A1         February 26, 2004         000           JP 07173070 A         July 11, 1995         006           TW 251238 A         July 11, 1995         000           CN 1106695 A         August 16, 1995         000           JP 3017630 B2         March 13, 2000         005           KR 149477 B1         October 15, 1998         000           LICATION-DATA:         APPL-DATE         APPL-NO         DESC           20040038330A1         June 9, 1994         1994US-0257355         Cont           20040038330A1         August 25, 1995         1995US-0519293         Div           20040038330A1         August 19, 2003         2003US-0644221         07173070A         December 17, 1993         1993JP-0317564           251238A         March 10, 1994         1994TW-0102087         1106695A         March 15, 1994         1994CN-0103012         3017630B2         December 17, 1993         1993JP-0317564         3017630B2         JP 7173070         Prev	

INT-CL (IPC): A61 K 35/66; A61 K 35/84; A61 P 31/12; C12 N 1/14; C12 N 9/42; C12 P  $\frac{1}{00}$ 

ABSTRACTED-PUB-NO: JP 07173070A
BASIC-ABSTRACT:

HIV virus activity inhibitor is prepd. by inoculating Lentinus edodes hypha onto bagasse solid medium and cultivating, dissociating the solid medium contg. proliferated hyphae, adding cellulase or protease to the medium at 30 to 50 degree C, extracting the hyphae in presence of the enzyme, inactivating the enzyme and sterilisation by heating to 95 deg. C.

USE/ADVANTAGE - The drug is used for treatment of  $\underline{\text{HIV}}$  infections. The drug inhibits  $\underline{\text{HIV}}$  proliferation and is highly safe. The drug at 125 microgram /ml inhibits the proliferation of  $\underline{\text{HIV}}$  inoculated on MT-4 cells.

In an example, <u>Lentinus edodes</u> was inoculated onto the wetted solid medium composing 90 pts.wt. of <u>bagasse</u> and 10 pts.wt. of rice bran, and cultivated. After the <u>hyphae</u> were proliferated, the <u>bagasse</u> fibres were dissociated by sieving. Then, 3.5 l pure water and 2.0 g <u>cellulase</u> were added to the medium (1.0 kg) at 40 degree C. The <u>bagasse</u> containing medium was circulated and ground using pump with speed change gear so that 80 wt.% of <u>bagasse</u> fibres were sieved through 12 mesh screen, heated to 90 degree C, left for 30 minutes, and filtrated through 60-mesh filter to give <u>Lentinus edodes hypha extract</u>.

ABSTRACTED-PUB-NO: JP 07173070A

**EQUIVALENT-ABSTRACTS:** 

CHOSEN-DRAWING: Dwg.0/1

DERWENT-CLASS: B04 D16

CPI-CODES: B04-F09; B14-A02B1; D05-A02C; D05-H01; D05-H06; D05-H08; D05-H13;

Previous Doc Next Doc Go to Doc#